We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Harrow Inc | NASDAQ:HROW | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.34 | -1.59% | 21.00 | 20.68 | 21.99 | 21.49 | 20.7521 | 21.34 | 496,005 | 01:00:00 |
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences:
BTIG 3rd Annual Ophthalmology Day Format: Fireside Chat (Virtual) Date/Time: Monday, November 27, 2023, at 1:30 p.m. ET
Piper Sandler 35th Annual Healthcare Conference (The Lotte New York Palace, New York, NY) Format: Fireside Chat (In-Person) Date/Time: Thursday, November 30, 2023, at 8:00 a.m. ET
Harrow management will be available for one-on-one meetings during both conferences. Investors interested in meeting with management should contact their BTIG or Piper Sandler representative to request a meeting.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120551397/en/
Jamie Webb, Director of Communications and Investor Relations jwebb@harrowinc.com 615-733-4737
1 Year Harrow Chart |
1 Month Harrow Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions